May 27, 2014 — IBA (Ion Beam Applications S.A.) announced the release of Compass 3.1 with the new Compass QuickCheck feature. Compass QuickCheck allows for fully automated gamma analysis in just one look, and automatic pass/fail is instantly indicated based on customers’ protocol thereby replacing human subjectivity. Compass now offers more efficiency and full workflow flexibility, allowing physicists and dosimetrists to choose the most efficient QA for any clinical need, whether measurement or calculation based.
“Compass is used to verify every IMRT and VMAT plan fast with 3-D computations. A huge advantage compared to other patient QA systems is the possibility of optionally conducting dose reconstructions based on MatriXX measurement,” said Mark P. Arends and Alle H. Ausma, medical physicists at Radiotherapy Institute Friesland, Leeuwarden, Netherlands. “Accidental linac dose delivery deviations from the treatment plan can be detected. The user can specify his own criteria for selecting the desired detection level. With the implemented 2-D QuickCheck, module deviations between expected and measured chamber response result automatically in a pass or fail indication.”
With its powerful Collapsed Cone Algorithm for independent dose calculations, Compass allows TPS-class dose calculations on real patient computed tomography (CT), real patient CT-based DVH, and global and local 3-D Gamma. Additionally, independent beam modeling of individual linacs enables flexibility in precisely modeling as many machines as needed for highly accurate plan verifications. Physicists can measure and compare real linac delivery vs. TPS-planned delivery as well as analyze the effect of segment errors on the total treatment accuracy.
“We are pleased to release the newest version of Compass with the new Compass QuickCheck, which offers significant efficiency that we feel is the most robust patient plan verification system available today. We are confident that this newest version of Compass is a huge step forward in the field of plan verification and provides safer radiation therapy,” remarked Ralf Schira, vice president of marketing for IBA Dosimetry.
For more information: www.iba-dosimetry.com
April 18, 2024 
